184 related articles for article (PubMed ID: 17520181)
1. Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys.
Kakkar T; Ma M; Zhuang Y; Patton A; Hu Z; Mounho B
Pharm Res; 2007 Oct; 24(10):1910-8. PubMed ID: 17520181
[TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
Gordon MS; Sweeney CS; Mendelson DS; Eckhardt SG; Anderson A; Beaupre DM; Branstetter D; Burgess TL; Coxon A; Deng H; Kaplan-Lefko P; Leitch IM; Oliner KS; Yan L; Zhu M; Gore L
Clin Cancer Res; 2010 Jan; 16(2):699-710. PubMed ID: 20068101
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of AMG 181, a human anti-α4 β7 antibody that specifically alters trafficking of gut-homing T cells.
Pan WJ; Hsu H; Rees WA; Lear SP; Lee F; Foltz IN; Rathanaswami P; Manchulenko K; Chan BM; Zhang M; Xia XZ; Patel SK; Prince PJ; Doherty DR; Sheckler CM; Reynhardt KO; Krill CD; Harder BJ; Wisler JA; Brandvig JL; Lynch JL; Anderson AA; Wienkers LC; Borie DC
Br J Pharmacol; 2013 May; 169(1):51-68. PubMed ID: 23425116
[TBL] [Abstract][Full Text] [Related]
4. Preclinical development of AMG 139, a human antibody specifically targeting IL-23.
Köck K; Pan WJ; Gow JM; Horner MJ; Gibbs JP; Colbert A; Goletz TJ; Newhall KJ; Rees WA; Sun Y; Zhang Y; O'Neill JC; Umble-Romero AN; Prokop SP; Krill CD; Som L; Buntich SA; Trimble MW; Tsuji WH; Towne JE
Br J Pharmacol; 2015 Jan; 172(1):159-72. PubMed ID: 25205227
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys.
Zia-Amirhosseini P; Minthorn E; Benincosa LJ; Hart TK; Hottenstein CS; Tobia LA; Davis CB
J Pharmacol Exp Ther; 1999 Dec; 291(3):1060-7. PubMed ID: 10565825
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys.
Xu L; Zuch CL; Lin YS; Modi NB; Lum BL
Cancer Chemother Pharmacol; 2008 Apr; 61(4):607-14. PubMed ID: 17549476
[TBL] [Abstract][Full Text] [Related]
7. Non-Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First-in-Human Dose Selection for CNTO 5825, an Anti-Interleukin-13 Monoclonal Antibody.
Nnane IP; Xu Z; Zhou H; Davis HM
Basic Clin Pharmacol Toxicol; 2015 Oct; 117(4):219-25. PubMed ID: 25683750
[TBL] [Abstract][Full Text] [Related]
8. Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor.
Skartved NJ; Jacobsen HJ; Pedersen MW; Jensen PF; Sen JW; Jørgensen TK; Hey A; Kragh M
Clin Cancer Res; 2011 Sep; 17(18):5962-72. PubMed ID: 21825041
[TBL] [Abstract][Full Text] [Related]
9. A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors.
Rosen PJ; Sweeney CJ; Park DJ; Beaupre DM; Deng H; Leitch IM; Shubhakar P; Zhu M; Oliner KS; Anderson A; Yee LK
Clin Cancer Res; 2010 May; 16(9):2677-87. PubMed ID: 20406832
[TBL] [Abstract][Full Text] [Related]
10. Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys.
Nnane IP; Han C; Jiao Q; Tam SH; Davis HM; Xu Z
Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):13-21. PubMed ID: 28132416
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy volunteers and knee osteoarthritis subjects.
Gow JM; Tsuji WH; Williams GJ; Mytych D; Sciberras D; Searle SL; Mant T; Gibbs JP
Arthritis Res Ther; 2015 Oct; 17():282. PubMed ID: 26449617
[TBL] [Abstract][Full Text] [Related]
12. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.
Herbst RS; Hong D; Chap L; Kurzrock R; Jackson E; Silverman JM; Rasmussen E; Sun YN; Zhong D; Hwang YC; Evelhoch JL; Oliner JD; Le N; Rosen LS
J Clin Oncol; 2009 Jul; 27(21):3557-65. PubMed ID: 19546406
[TBL] [Abstract][Full Text] [Related]
13. Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate.
Binz HK; Bakker TR; Phillips DJ; Cornelius A; Zitt C; Göttler T; Sigrist G; Fiedler U; Ekawardhani S; Dolado I; Saliba JA; Tresch G; Proba K; Stumpp MT
MAbs; 2017; 9(8):1262-1269. PubMed ID: 29035637
[TBL] [Abstract][Full Text] [Related]
14. A multiple-dose toxicity study of tanezumab in cynomolgus monkeys.
Zorbas M; Hurst S; Shelton D; Evans M; Finco D; Butt M
Regul Toxicol Pharmacol; 2011 Mar; 59(2):334-42. PubMed ID: 21130822
[TBL] [Abstract][Full Text] [Related]
15. Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: relevance for human safety.
Ryan PC; Sleeman MA; Rebelatto M; Wang B; Lu H; Chen X; Wu CY; Hinrichs MJ; Roskos L; Towers H; McKeever K; Dixit R
Toxicol Appl Pharmacol; 2014 Sep; 279(2):230-9. PubMed ID: 24937321
[TBL] [Abstract][Full Text] [Related]
16. Onartuzumab (MetMAb): using nonclinical pharmacokinetic and concentration-effect data to support clinical development.
Xiang H; Bender BC; Reyes AE; Merchant M; Jumbe NL; Romero M; Davancaze T; Nijem I; Mai E; Young J; Peterson A; Damico-Beyer LA
Clin Cancer Res; 2013 Sep; 19(18):5068-78. PubMed ID: 23894056
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours.
Gibiansky L; Sutjandra L; Doshi S; Zheng J; Sohn W; Peterson MC; Jang GR; Chow AT; Pérez-Ruixo JJ
Clin Pharmacokinet; 2012 Apr; 51(4):247-60. PubMed ID: 22420579
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma.
Schöffski P; Garcia JA; Stadler WM; Gil T; Jonasch E; Tagawa ST; Smitt M; Yang X; Oliner KS; Anderson A; Zhu M; Kabbinavar F
BJU Int; 2011 Sep; 108(5):679-86. PubMed ID: 21156020
[TBL] [Abstract][Full Text] [Related]
19. Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor.
Burgess TL; Sun J; Meyer S; Tsuruda TS; Sun J; Elliott G; Chen Q; Haniu M; Barron WF; Juan T; Zhang K; Coxon A; Kendall RL
Mol Cancer Ther; 2010 Feb; 9(2):400-9. PubMed ID: 20124448
[TBL] [Abstract][Full Text] [Related]
20. Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: A reversible non-covalent albumin-binding growth hormone.
Thygesen P; Andersen HS; Behrens C; Fels JJ; Nørskov-Lauritsen L; Rischel C; Johansen NL
Growth Horm IGF Res; 2017 Aug; 35():8-16. PubMed ID: 28595133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
